![iconArrow](/media/ovbjzzzd/iconarrow.png)
Zevor-cel (CT053)3
Zevor-cel (CT053)
Zevor-cel (CT053)
Conventional
Zevorcabtagene autoleucel (Zevor-cel, R&D code: CT053) is a fully human, autologous BCMA CAR T-cell product for the treatment of R/R MM. Zevorcabtagene autoleucel was approved by the NMPA on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (at least one proteasome inhibitor and immunomodulator).
![](/media/bxjp40qm/china.jpg)
![](/media/kuhbyw3g/trophy.jpg)
for relapsed and/or refractory multiple myeloma (R/R MM)
![](/media/kuhbyw3g/trophy.jpg)
for relapsed and/or refractory multiple myeloma (R/R MM)
![](/media/kuhbyw3g/trophy.jpg)
Breakthrough Therapy Designation, NMPA
for relapsed and/or refractory multiple myeloma (R/R MM)
![](/media/kuhbyw3g/trophy.jpg)
for multiple myeloma (MM)
![](/media/kuhbyw3g/trophy.jpg)
Orphan Drug designation, EMA
for multiple myeloma (MM)
Conventional
CT041
CT041
CT041
Conventional
CT041 is an autologous CAR T product candidate that targets Claudin18.2 (“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.
![](/media/kuhbyw3g/trophy.jpg)
for advanced gastric /gastroesophageal junction adenocarcinoma (GC/GEJ) with Claudin18.2-positive tumor
![](/media/kuhbyw3g/trophy.jpg)
for advanced gastric cancer
![](/media/kuhbyw3g/trophy.jpg)
for gastric /gastroesophageal junction cancer (GC/GEJ)
![](/media/kuhbyw3g/trophy.jpg)
Orphan Drug designation, EMA
for advanced gastric cancer
Conventional
CT011
CT011
CT011
Conventional
CT011 is an autologous CAR T product candidate that targets glypican-3 (GPC3), which is highly expressed in HCC and is suggested to be a prognostic marker for the disease.
![](/media/bxjp40qm/china.jpg)
Investigator-initiated trials
Phase I trial for GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection
Conventional
CT071
CT071
CT071
CARcelerate®
CT071 is a CAR T-cell therapy candidate developed utilizing our proprietary CARcelerate® platform, targeting GPRC5D. CARcelerate® platform can shorten the manufacturing time for the CAR T cells to about 30 hours.
CARcelerate®
sFv-ε
sFv-ε
THANK-uCAR®
CycloCAR®
CycloCAR®
THANK-uCAR®
Undisclosed
![iconArrow](/media/ovbjzzzd/iconarrow.png)
AB011
AB011
AB011
AB011 is a humanized monoclonal antibody product candidate that targets Claudin18.2(“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.
![](/media/bxjp40qm/china.jpg)
Phase I Clinical Trial for CLDN18.2 Positive Advanced GC/GEJ and PC (AB011-ST-01)
R/R MM: relapsed/refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal junction cancer; PC: pancreatic cancer; HCC: hepatocellular carcinoma; R/R pPCL: relapsed/refractory primary plasma cell leukemia; NDMM: newly diagnosed multiple myeloma; AML: acute myeloid leukemia
1 All product candidates are self-developed with global rights
2 Phase II trials of some indications are pivotal studies
3 Core Product Candidate. Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940)